TransCon TLR7/8 Agonist for Cancer
This study is evaluating whether a drug may help treat cancer.
See full descriptionAbout the trial for Cancer
Treatment Groups
This trial involves 3 different treatments. TransCon TLR7/8 Agonist is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Cancer or one of the other 3 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether TransCon TLR7/8 Agonist will improve 3 primary outcomes and 10 secondary outcomes in patients with Cancer. Measurement will happen over the course of Cycle 1 (each cycle is 21 days) in Part 1 (monotherapy dose escalation) and Cycle 1 (the first cycle is 28 days and 21 days thereafter) in Part 2 (combination therapy dose escalation).
Patient Q & A Section
How many people get cancer a year in the United States?
Approximately 8.7 million Americans get cancer a year; this is 12% of men and a staggering 13% of women. Cancer incidence rates are high in older adults, especially women.
What is cancer?
The word cancer originates in the Greek language, referring to the production of deadly substances. This concept refers to the fact that cancer is a disease characterized by uncontrolled cell growth and the infiltration of tumor cells into healthy tissues. The word "cancer" comes from the Greek words, "kykoros", a flesh-eating worm, translated as "the devouring one", and "komos", meaning "poison", which signifies "the deadly disease".\n
Can cancer be cured?
Because cancer can be treated, cure is not necessarily possible. The treatment of metastatic cancer that had spread beyond the area of origin (i.e., that had metastasized) was almost as successful as treating localized cancer (i.e., that had not spread beyond the area of origin).
What are common treatments for cancer?
There were multiple common treatments for a large number of different cancers. A systematic review of the literature should be performed, which would aid in identifying the treatment guidelines of cancer management.
What causes cancer?
It is not clear what specific risk factors determine which individuals will develop cancer. Genetic factors may have some impact but not enough to make an individual substantially worse off than someone else. The environment is an important factor. Tobacco smoke appears to be perhaps the most dangerous factor in cancer.
What are the signs of cancer?
Cancer can cause chronic symptoms which could be mistaken for benign conditions including the common cold, influenza and gastroenteritis. Most people with cancer remain symptom-free, but most people with cancer develop symptomatology. Symptoms may be experienced long enough to interfere with quality of life and cause problems with social and daily activities, though not necessarily long enough to necessitate treatment until cancer progresses. Symptoms may also be experienced by people in their early years, prior to discovering that there is a disease in their body, and thus may be misinterpreted as normal. Symptoms can be assessed by a multidisciplinary health care team.
Does cancer run in families?
Cancer predisposes to the development of cancer in a relative, particularly if the affected members may carry a mutated genetic predisposition, but does not confer familial disease itself. These data raise questions about the value of genetic counseling to the entire family and indicate that some cases with a family history of cancer may be avoided by testing affected relatives for their disease specific genetic variations, even those without a known family history.
How serious can cancer be?
Although cancer is an acute disease that can progress rapidly and cause sudden death, the number of patients who survive is much greater. This finding makes it difficult to understand and understand the seriousness of the disease, especially when cancer is the cause of serious illness without obvious symptoms. In a clinical setting, the patient’s vital signs, including pulse rate, respiration, body temperature, and blood glucose level, should be monitored frequently in an effort to identify the earliest signs of disease progression (symptoms) and to stop it before it is too serious and fatal.
What does transcon tlr7/8 agonist usually treat?
O6GTX-A binds to a trans-molecular ligand receptor, which is an ATP-binding cassette transporter, and can activate T lr7/8 signaling. O6GTX-A is a potential new substance therapeutic target for non-small cell lung cancer.
What are the latest developments in transcon tlr7/8 agonist for therapeutic use?
The development of the transcon-TLR7/8 agonists in the past 10 years (2012) has resulted in a range of molecular configurations within a small molecule drug space that can induce activation of toll-like receptors. These data can now be used to inform drug design and optimization of drug potency. At this stage we have focused on the rational development of these molecules as therapeutics, with further evaluation of drug action in animals and development as human therapeutics anticipated. In addition, further exploration of these molecules is planned in the near future to investigate their potential use in the clinic. Clin Cancer Res; 22(23); 4974-84.
What is transcon tlr7/8 agonist?
TLR7/8 is the most well-known ligand for TRIF/TRIFR2 signaling of this pathway that recognizes viral double-stranded RNA in Viral infection in a TLR7 or TLR8-dependent way. Viral dsRNA sensed by TLR7 triggers the production of interferon-β, thus stimulating NK cell cytotoxicity that has been used in cancer eradication therapy. So, we can conclude that TLR7 and TLR8 ligands act to the opposite way. But this theory was in the past proved incorrect by the discovery of RIG-I receptors. There are several reasons in addition which are still unclear.
What is the latest research for cancer?
Results of clinical trials must be analysed carefully before conclusions can be drawn about the drug's effect. In the last twenty years, studies in the areas of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) treatments, and ovarian cancer have shown very positive effects. However, the majority of studies on cancer are from small randomized controlled studies and some are not blinded for all the treatment. Some results are contradictory. Therefore, we look to randomized studies for the safest conclusions.